secwatch.observer — SEC 8-K summary
======================================

Issuer:     TITAN PHARMACEUTICALS INC (—)
CIK:        0000910267
Form:       8-K
Filed at:   2025-10-01T23:59:59+00:00
Accession:  0001829126-25-007823
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.03, 5.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Titan Pharmaceuticals completes merger with Black Titan; shares to cease trading on Nasdaq
--------------------------------------------------------------------------------

- On Oct 1, 2025, Titan merged with Black Titan subsidiary; TTNP shares convert to PubCo ordinary shares.
- TalenTec shareholders contributed shares for PubCo shares; PubCo shares to start trading Oct 2 on Nasdaq.
- All TTNP directors and officers resigned; Chay Weei Jye appointed as sole director and acting secretary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/910267/000182912625007823/0001829126-25-007823-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/910267/000182912625007823/titanpharma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-25-007823

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer